 Jonathan Chung
Concepts (566)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 96 | 2021 | 2569 | 12.870 |
Why?
| | Lung Diseases, Interstitial | 32 | 2021 | 218 | 10.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 21 | 2021 | 146 | 7.770 |
Why?
| | Lung | 33 | 2021 | 1061 | 5.280 |
Why?
| | Radiography, Thoracic | 21 | 2020 | 322 | 4.130 |
Why?
| | Lung Neoplasms | 24 | 2022 | 2119 | 3.420 |
Why?
| | Alveolitis, Extrinsic Allergic | 5 | 2020 | 30 | 2.350 |
Why?
| | Diagnosis, Differential | 33 | 2020 | 1605 | 2.290 |
Why?
| | Lymph Nodes | 7 | 2019 | 532 | 2.210 |
Why?
| | Diagnostic Imaging | 14 | 2021 | 454 | 2.180 |
Why?
| | Humans | 191 | 2022 | 83447 | 2.100 |
Why?
| | Lung Diseases | 10 | 2021 | 268 | 1.920 |
Why?
| | Connective Tissue Diseases | 5 | 2021 | 70 | 1.770 |
Why?
| | Urinary Bladder Neoplasms | 9 | 2021 | 334 | 1.730 |
Why?
| | Idiopathic Interstitial Pneumonias | 9 | 2019 | 32 | 1.660 |
Why?
| | Practice Guidelines as Topic | 11 | 2020 | 1087 | 1.650 |
Why?
| | Solitary Pulmonary Nodule | 5 | 2018 | 138 | 1.640 |
Why?
| | Middle Aged | 81 | 2021 | 25596 | 1.610 |
Why?
| | Dyspnea | 5 | 2020 | 80 | 1.590 |
Why?
| | Incidental Findings | 5 | 2018 | 95 | 1.570 |
Why?
| | Aged | 64 | 2021 | 18508 | 1.510 |
Why?
| | Utilization Review | 2 | 2019 | 23 | 1.510 |
Why?
| | Pulmonary Fibrosis | 7 | 2021 | 119 | 1.450 |
Why?
| | Radiology | 11 | 2019 | 179 | 1.410 |
Why?
| | Multiple Pulmonary Nodules | 3 | 2018 | 6 | 1.390 |
Why?
| | Male | 87 | 2021 | 41899 | 1.360 |
Why?
| | Thoracic Injuries | 6 | 2020 | 29 | 1.360 |
Why?
| | Female | 87 | 2021 | 44784 | 1.340 |
Why?
| | Radiology Department, Hospital | 2 | 2018 | 26 | 1.340 |
Why?
| | Wounds, Nonpenetrating | 4 | 2020 | 73 | 1.330 |
Why?
| | Cough | 3 | 2020 | 49 | 1.310 |
Why?
| | Interdisciplinary Communication | 2 | 2018 | 127 | 1.280 |
Why?
| | Societies, Medical | 17 | 2021 | 572 | 1.270 |
Why?
| | Aortic Diseases | 3 | 2019 | 107 | 1.250 |
Why?
| | Diagnostic Errors | 2 | 2018 | 168 | 1.220 |
Why?
| | Aorta, Thoracic | 3 | 2019 | 173 | 1.210 |
Why?
| | Biopsy | 9 | 2021 | 1182 | 1.190 |
Why?
| | Genomics | 12 | 2021 | 648 | 1.130 |
Why?
| | Magnetic Resonance Imaging | 11 | 2021 | 3267 | 1.080 |
Why?
| | Scleroderma, Systemic | 3 | 2020 | 40 | 1.070 |
Why?
| | Reproducibility of Results | 13 | 2021 | 2674 | 1.060 |
Why?
| | BRCA2 Protein | 3 | 2021 | 137 | 1.040 |
Why?
| | Sensitivity and Specificity | 14 | 2021 | 2080 | 1.000 |
Why?
| | Mediastinum | 3 | 2019 | 50 | 0.990 |
Why?
| | Mucin-5B | 3 | 2019 | 13 | 0.980 |
Why?
| | Carcinoma, Transitional Cell | 6 | 2020 | 155 | 0.960 |
Why?
| | Contrast Media | 14 | 2019 | 1083 | 0.950 |
Why?
| | Coronary Artery Disease | 5 | 2019 | 372 | 0.950 |
Why?
| | Retrospective Studies | 27 | 2021 | 7644 | 0.930 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 984 | 0.910 |
Why?
| | Predictive Value of Tests | 7 | 2021 | 1758 | 0.900 |
Why?
| | Phthalazines | 2 | 2018 | 30 | 0.900 |
Why?
| | Radiology Information Systems | 3 | 2018 | 78 | 0.890 |
Why?
| | Pulmonary Embolism | 3 | 2020 | 202 | 0.880 |
Why?
| | Pleura | 3 | 2020 | 31 | 0.880 |
Why?
| | Sarcoidosis, Pulmonary | 3 | 2019 | 17 | 0.870 |
Why?
| | Coronary Angiography | 8 | 2019 | 232 | 0.850 |
Why?
| | Pulmonary Artery | 4 | 2019 | 298 | 0.840 |
Why?
| | Piperazines | 3 | 2020 | 270 | 0.830 |
Why?
| | Survival Analysis | 5 | 2018 | 1584 | 0.820 |
Why?
| | Lymphatic Metastasis | 5 | 2019 | 508 | 0.820 |
Why?
| | Early Detection of Cancer | 3 | 2018 | 313 | 0.820 |
Why?
| | Fluorodeoxyglucose F18 | 8 | 2018 | 126 | 0.810 |
Why?
| | Radiopharmaceuticals | 8 | 2018 | 173 | 0.800 |
Why?
| | Quality Assurance, Health Care | 2 | 2018 | 227 | 0.790 |
Why?
| | Pleural Diseases | 2 | 2016 | 13 | 0.780 |
Why?
| | Granuloma | 3 | 2016 | 52 | 0.770 |
Why?
| | Adult | 46 | 2021 | 25995 | 0.770 |
Why?
| | Positron-Emission Tomography | 6 | 2016 | 273 | 0.770 |
Why?
| | Pulmonary Alveoli | 2 | 2016 | 84 | 0.740 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 27 | 0.740 |
Why?
| | Allied Health Personnel | 1 | 2018 | 17 | 0.720 |
Why?
| | United States | 25 | 2021 | 6316 | 0.720 |
Why?
| | Autoimmune Diseases | 2 | 2017 | 233 | 0.720 |
Why?
| | Cohort Studies | 13 | 2021 | 2710 | 0.710 |
Why?
| | Urothelium | 1 | 2018 | 63 | 0.710 |
Why?
| | Feedback | 1 | 2018 | 113 | 0.700 |
Why?
| | Technology, Radiologic | 1 | 2018 | 102 | 0.690 |
Why?
| | Gadolinium | 3 | 2014 | 113 | 0.660 |
Why?
| | Physician Incentive Plans | 1 | 2016 | 21 | 0.660 |
Why?
| | Efficiency | 1 | 2016 | 39 | 0.660 |
Why?
| | Prognosis | 15 | 2021 | 3709 | 0.660 |
Why?
| | Speech Recognition Software | 1 | 2016 | 5 | 0.650 |
Why?
| | Evidence-Based Medicine | 13 | 2021 | 453 | 0.650 |
Why?
| | Medical Audit | 1 | 2016 | 38 | 0.640 |
Why?
| | Tracheomalacia | 1 | 2016 | 2 | 0.640 |
Why?
| | Peer Review | 1 | 2016 | 21 | 0.640 |
Why?
| | Prevalence | 8 | 2021 | 1264 | 0.630 |
Why?
| | Fibrosis | 6 | 2020 | 191 | 0.630 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2016 | 7 | 0.630 |
Why?
| | Medical Records | 1 | 2016 | 120 | 0.630 |
Why?
| | Bronchiolitis Obliterans | 1 | 2016 | 45 | 0.610 |
Why?
| | Gases | 1 | 2015 | 28 | 0.600 |
Why?
| | Breast Implants | 1 | 2015 | 32 | 0.600 |
Why?
| | Birt-Hogg-Dube Syndrome | 2 | 2014 | 3 | 0.600 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2020 | 123 | 0.590 |
Why?
| | Cryptogenic Organizing Pneumonia | 2 | 2012 | 6 | 0.590 |
Why?
| | Lymphangioleiomyomatosis | 2 | 2014 | 9 | 0.590 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2014 | 18 | 0.580 |
Why?
| | Calcinosis | 1 | 2016 | 241 | 0.580 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2013 | 189 | 0.580 |
Why?
| | Tracheal Diseases | 2 | 2013 | 12 | 0.580 |
Why?
| | Academic Medical Centers | 2 | 2018 | 393 | 0.570 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 434 | 0.570 |
Why?
| | Psoriasis | 4 | 2018 | 222 | 0.570 |
Why?
| | Mutation | 11 | 2022 | 3862 | 0.560 |
Why?
| | Faculty, Medical | 1 | 2016 | 167 | 0.560 |
Why?
| | Lung Transplantation | 2 | 2018 | 237 | 0.560 |
Why?
| | Carcinoma | 1 | 2018 | 440 | 0.560 |
Why?
| | Lymphatic Diseases | 1 | 2014 | 38 | 0.550 |
Why?
| | Cysts | 2 | 2014 | 100 | 0.550 |
Why?
| | Motivation | 1 | 2016 | 260 | 0.550 |
Why?
| | Lung Diseases, Obstructive | 1 | 2014 | 23 | 0.550 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2021 | 940 | 0.550 |
Why?
| | Pulmonary Valve | 2 | 2020 | 28 | 0.540 |
Why?
| | Chronic Disease | 7 | 2020 | 968 | 0.530 |
Why?
| | Observer Variation | 4 | 2020 | 621 | 0.530 |
Why?
| | Testicular Neoplasms | 3 | 2019 | 109 | 0.520 |
Why?
| | Disease Progression | 7 | 2021 | 1474 | 0.510 |
Why?
| | Sarcoidosis | 1 | 2014 | 89 | 0.510 |
Why?
| | Cystectomy | 5 | 2021 | 69 | 0.510 |
Why?
| | Pulmonary Circulation | 2 | 2012 | 85 | 0.510 |
Why?
| | Ventricular Septum | 1 | 2012 | 14 | 0.500 |
Why?
| | Arthritis, Rheumatoid | 3 | 2021 | 156 | 0.500 |
Why?
| | Pulmonary Subvalvular Stenosis | 1 | 2012 | 1 | 0.500 |
Why?
| | Mass Screening | 1 | 2017 | 623 | 0.490 |
Why?
| | Image Enhancement | 2 | 2013 | 585 | 0.480 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 2012 | 75 | 0.480 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2020 | 1036 | 0.480 |
Why?
| | Systole | 1 | 2012 | 142 | 0.480 |
Why?
| | Aneurysm | 1 | 2012 | 58 | 0.470 |
Why?
| | Lymphomatoid Granulomatosis | 1 | 2011 | 6 | 0.470 |
Why?
| | Echocardiography | 4 | 2020 | 892 | 0.470 |
Why?
| | Myocardial Ischemia | 1 | 2013 | 167 | 0.470 |
Why?
| | Smoking | 3 | 2017 | 569 | 0.470 |
Why?
| | Kidney Neoplasms | 4 | 2021 | 590 | 0.460 |
Why?
| | Pulmonary Infarction | 1 | 2010 | 1 | 0.440 |
Why?
| | Immunocompromised Host | 3 | 2019 | 144 | 0.440 |
Why?
| | Aged, 80 and over | 13 | 2021 | 6577 | 0.430 |
Why?
| | Inhalation Exposure | 2 | 2021 | 28 | 0.430 |
Why?
| | Hematoma | 1 | 2011 | 96 | 0.430 |
Why?
| | Mucormycosis | 1 | 2010 | 15 | 0.430 |
Why?
| | Coronavirus Infections | 3 | 2020 | 284 | 0.430 |
Why?
| | Lung Diseases, Fungal | 1 | 2010 | 27 | 0.430 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 310 | 0.430 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2020 | 413 | 0.420 |
Why?
| | Mitral Valve | 1 | 2012 | 233 | 0.420 |
Why?
| | Molecular Targeted Therapy | 4 | 2020 | 273 | 0.410 |
Why?
| | Amyloidosis | 1 | 2010 | 78 | 0.410 |
Why?
| | Plaque, Atherosclerotic | 3 | 2019 | 41 | 0.400 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2009 | 5 | 0.400 |
Why?
| | Antineoplastic Agents | 6 | 2019 | 2362 | 0.400 |
Why?
| | Graft Rejection | 1 | 2016 | 1110 | 0.390 |
Why?
| | Heart Diseases | 1 | 2012 | 314 | 0.380 |
Why?
| | Colorado | 3 | 2019 | 36 | 0.380 |
Why?
| | Phenotype | 6 | 2019 | 2295 | 0.380 |
Why?
| | Receptor, erbB-2 | 3 | 2020 | 193 | 0.380 |
Why?
| | Radiographic Image Enhancement | 4 | 2016 | 466 | 0.380 |
Why?
| | Adenocarcinoma | 4 | 2020 | 1195 | 0.380 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 273 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2313 | 0.360 |
Why?
| | Asthma | 1 | 2016 | 889 | 0.350 |
Why?
| | Aorta | 2 | 2020 | 298 | 0.340 |
Why?
| | Carcinoma, Renal Cell | 3 | 2021 | 397 | 0.340 |
Why?
| | Neoplasm Invasiveness | 5 | 2021 | 532 | 0.340 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 348 | 0.340 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2019 | 93 | 0.340 |
Why?
| | Respiratory Tract Diseases | 2 | 2018 | 44 | 0.340 |
Why?
| | Respiratory Tract Infections | 3 | 2019 | 100 | 0.330 |
Why?
| | Gene Rearrangement | 4 | 2020 | 169 | 0.330 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 250 | 0.330 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 410 | 0.330 |
Why?
| | Gene Expression Profiling | 4 | 2021 | 1367 | 0.330 |
Why?
| | Respiratory-Gated Imaging Techniques | 2 | 2016 | 4 | 0.320 |
Why?
| | Genotype | 4 | 2017 | 1856 | 0.320 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1011 | 0.310 |
Why?
| | Hematologic Neoplasms | 1 | 2009 | 295 | 0.310 |
Why?
| | DiGeorge Syndrome | 2 | 2017 | 15 | 0.300 |
Why?
| | Cardiovascular Diseases | 3 | 2018 | 815 | 0.300 |
Why?
| | Liver Neoplasms | 3 | 2017 | 634 | 0.290 |
Why?
| | Algorithms | 7 | 2019 | 1847 | 0.290 |
Why?
| | Anthracosis | 2 | 2022 | 2 | 0.290 |
Why?
| | Feasibility Studies | 3 | 2020 | 759 | 0.280 |
Why?
| | Rheumatoid Factor | 2 | 2021 | 26 | 0.280 |
Why?
| | Stroke | 1 | 2012 | 792 | 0.270 |
Why?
| | Thoracic Wall | 2 | 2021 | 21 | 0.270 |
Why?
| | Angiography | 3 | 2014 | 212 | 0.270 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1925 | 0.270 |
Why?
| | Treatment Outcome | 10 | 2020 | 7905 | 0.270 |
Why?
| | Hypertension, Pulmonary | 3 | 2018 | 341 | 0.260 |
Why?
| | Carcinoma, Bronchogenic | 2 | 2013 | 30 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2020 | 1209 | 0.250 |
Why?
| | Biological Specimen Banks | 2 | 2020 | 46 | 0.250 |
Why?
| | Hemoptysis | 2 | 2014 | 24 | 0.250 |
Why?
| | Risk Factors | 9 | 2021 | 5418 | 0.240 |
Why?
| | Multidetector Computed Tomography | 3 | 2019 | 57 | 0.240 |
Why?
| | Pancreatic Neoplasms | 2 | 2019 | 674 | 0.240 |
Why?
| | Serologic Tests | 2 | 2020 | 45 | 0.240 |
Why?
| | Software | 3 | 2018 | 643 | 0.240 |
Why?
| | Medical History Taking | 2 | 2020 | 83 | 0.230 |
Why?
| | Mediastinal Diseases | 1 | 2021 | 24 | 0.230 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 41 | 0.230 |
Why?
| | Urethral Neoplasms | 1 | 2021 | 9 | 0.230 |
Why?
| | Genetic Variation | 2 | 2019 | 1361 | 0.230 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 39 | 0.230 |
Why?
| | Carcinoma, Medullary | 1 | 2021 | 14 | 0.230 |
Why?
| | Oncogene Fusion | 1 | 2020 | 6 | 0.220 |
Why?
| | Atrial Septum | 2 | 2010 | 9 | 0.220 |
Why?
| | Urogenital Neoplasms | 1 | 2020 | 17 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 579 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2020 | 2779 | 0.220 |
Why?
| | Fibroblast Growth Factor 3 | 1 | 2020 | 2 | 0.220 |
Why?
| | Occupational Health | 1 | 2021 | 34 | 0.220 |
Why?
| | Ureteral Neoplasms | 1 | 2020 | 17 | 0.220 |
Why?
| | Neoadjuvant Therapy | 5 | 2021 | 272 | 0.220 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 14 | 0.220 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 24 | 0.220 |
Why?
| | Thoracic Outlet Syndrome | 1 | 2020 | 2 | 0.210 |
Why?
| | Acute Lung Injury | 1 | 2021 | 54 | 0.210 |
Why?
| | Gastropexy | 1 | 2020 | 1 | 0.210 |
Why?
| | Receptors, Androgen | 1 | 2021 | 92 | 0.210 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2010 | 63 | 0.210 |
Why?
| | Pandemics | 3 | 2020 | 538 | 0.210 |
Why?
| | Ossification, Heterotopic | 1 | 2020 | 34 | 0.210 |
Why?
| | Bronchiolitis | 3 | 2015 | 4 | 0.210 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 584 | 0.210 |
Why?
| | Prospective Studies | 8 | 2021 | 4085 | 0.210 |
Why?
| | Occupational Exposure | 1 | 2021 | 75 | 0.210 |
Why?
| | Internship and Residency | 1 | 2009 | 904 | 0.210 |
Why?
| | Registries | 3 | 2021 | 662 | 0.210 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 131 | 0.210 |
Why?
| | Radiation Dosage | 2 | 2019 | 226 | 0.210 |
Why?
| | France | 1 | 2020 | 51 | 0.210 |
Why?
| | Brazil | 1 | 2020 | 69 | 0.200 |
Why?
| | Coronavirus | 1 | 2020 | 16 | 0.200 |
Why?
| | Risk Assessment | 5 | 2021 | 2284 | 0.200 |
Why?
| | Piperidines | 2 | 2018 | 191 | 0.200 |
Why?
| | Genome | 2 | 2020 | 360 | 0.200 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 28 | 0.200 |
Why?
| | Gastrostomy | 1 | 2020 | 76 | 0.200 |
Why?
| | Translocation, Genetic | 1 | 2020 | 263 | 0.200 |
Why?
| | Survival Rate | 3 | 2019 | 1919 | 0.200 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 44 | 0.200 |
Why?
| | BRCA1 Protein | 1 | 2021 | 182 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2338 | 0.200 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 116 | 0.200 |
Why?
| | Autoimmunity | 2 | 2018 | 163 | 0.200 |
Why?
| | Medicare Part B | 1 | 2019 | 3 | 0.200 |
Why?
| | Immunoglobulin A | 1 | 2019 | 98 | 0.200 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 15 | 0.200 |
Why?
| | Arthritis, Psoriatic | 1 | 2019 | 32 | 0.190 |
Why?
| | Urologic Neoplasms | 1 | 2020 | 74 | 0.190 |
Why?
| | Hematopoietic System | 1 | 2018 | 14 | 0.190 |
Why?
| | Hemorrhage | 1 | 2021 | 248 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2018 | 18 | 0.190 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2019 | 46 | 0.190 |
Why?
| | Artifacts | 3 | 2019 | 247 | 0.190 |
Why?
| | Referral and Consultation | 2 | 2019 | 324 | 0.190 |
Why?
| | Mediastinal Neoplasms | 1 | 2019 | 48 | 0.190 |
Why?
| | Seminoma | 1 | 2018 | 12 | 0.190 |
Why?
| | Quinazolines | 2 | 2018 | 220 | 0.190 |
Why?
| | Carcinoma, Large Cell | 1 | 2018 | 41 | 0.190 |
Why?
| | Bronchoscopy | 5 | 2021 | 147 | 0.190 |
Why?
| | Parathyroid Neoplasms | 1 | 2018 | 64 | 0.180 |
Why?
| | Databases, Factual | 2 | 2020 | 789 | 0.180 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 134 | 0.180 |
Why?
| | Autoantibodies | 1 | 2019 | 257 | 0.180 |
Why?
| | Comparative Effectiveness Research | 2 | 2016 | 48 | 0.180 |
Why?
| | Statistics as Topic | 2 | 2017 | 243 | 0.180 |
Why?
| | Carbazoles | 1 | 2018 | 52 | 0.180 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2019 | 66 | 0.180 |
Why?
| | Lipoproteins, HDL | 1 | 2018 | 113 | 0.180 |
Why?
| | Drug Substitution | 1 | 2018 | 27 | 0.180 |
Why?
| | Pneumonectomy | 1 | 2020 | 186 | 0.180 |
Why?
| | Amygdala | 1 | 2018 | 81 | 0.180 |
Why?
| | Occupational Diseases | 2 | 2016 | 54 | 0.180 |
Why?
| | Lymphocytes | 1 | 2020 | 477 | 0.180 |
Why?
| | Pulmonary Emphysema | 1 | 2017 | 24 | 0.180 |
Why?
| | Vasculitis | 1 | 2017 | 40 | 0.180 |
Why?
| | Free Radical Scavengers | 1 | 2018 | 64 | 0.180 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 512 | 0.180 |
Why?
| | Subcutaneous Fat | 1 | 2017 | 21 | 0.180 |
Why?
| | Intra-Abdominal Fat | 1 | 2017 | 29 | 0.180 |
Why?
| | Tetralogy of Fallot | 1 | 2017 | 43 | 0.170 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2018 | 79 | 0.170 |
Why?
| | Acetylcysteine | 1 | 2018 | 76 | 0.170 |
Why?
| | Adiposity | 1 | 2017 | 72 | 0.170 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2017 | 29 | 0.170 |
Why?
| | Antirheumatic Agents | 1 | 2017 | 53 | 0.170 |
Why?
| | Coronary Vessels | 1 | 2019 | 187 | 0.170 |
Why?
| | Salaries and Fringe Benefits | 1 | 2016 | 20 | 0.170 |
Why?
| | Transcriptome | 1 | 2021 | 516 | 0.170 |
Why?
| | Radionuclide Imaging | 1 | 2017 | 236 | 0.170 |
Why?
| | Case-Control Studies | 3 | 2018 | 1825 | 0.170 |
Why?
| | Pathology, Clinical | 1 | 2017 | 37 | 0.170 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 463 | 0.170 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2016 | 23 | 0.160 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 4 | 0.160 |
Why?
| | Software Validation | 1 | 2016 | 3 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2017 | 126 | 0.160 |
Why?
| | Hyperlipidemias | 1 | 2017 | 133 | 0.160 |
Why?
| | Mycobacterium avium Complex | 1 | 2016 | 9 | 0.160 |
Why?
| | Myositis | 1 | 2016 | 17 | 0.160 |
Why?
| | Repressor Proteins | 1 | 2019 | 409 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2017 | 359 | 0.160 |
Why?
| | Promoter Regions, Genetic | 2 | 2019 | 942 | 0.160 |
Why?
| | Azathioprine | 1 | 2016 | 126 | 0.160 |
Why?
| | Atmospheric Pressure | 1 | 2015 | 4 | 0.160 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 160 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2018 | 234 | 0.150 |
Why?
| | Altitude | 1 | 2015 | 42 | 0.150 |
Why?
| | Hospitalization | 2 | 2018 | 767 | 0.150 |
Why?
| | Neuroendocrine Cells | 1 | 2015 | 2 | 0.150 |
Why?
| | Stress, Psychological | 1 | 2018 | 308 | 0.150 |
Why?
| | Rib Fractures | 1 | 2014 | 4 | 0.150 |
Why?
| | Atrial Fibrillation | 1 | 2018 | 269 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2018 | 685 | 0.140 |
Why?
| | Cystic Fibrosis | 1 | 2016 | 128 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 223 | 0.140 |
Why?
| | Pneumonia, Aspiration | 1 | 2014 | 19 | 0.140 |
Why?
| | Nuclear Proteins | 1 | 2019 | 697 | 0.140 |
Why?
| | Guideline Adherence | 1 | 2016 | 225 | 0.140 |
Why?
| | Heterozygote | 1 | 2016 | 374 | 0.140 |
Why?
| | Acute Disease | 4 | 2019 | 862 | 0.140 |
Why?
| | Prosthesis Failure | 1 | 2015 | 147 | 0.140 |
Why?
| | Cardiac Imaging Techniques | 1 | 2014 | 29 | 0.140 |
Why?
| | Emphysema | 1 | 2014 | 16 | 0.140 |
Why?
| | Biopsy, Needle | 2 | 2012 | 268 | 0.140 |
Why?
| | Glass | 1 | 2014 | 15 | 0.140 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2014 | 8 | 0.140 |
Why?
| | Heart Ventricles | 1 | 2020 | 790 | 0.140 |
Why?
| | Immunosuppressive Agents | 2 | 2016 | 1026 | 0.130 |
Why?
| | Bronchial Diseases | 1 | 2013 | 12 | 0.130 |
Why?
| | User-Computer Interface | 2 | 2012 | 186 | 0.130 |
Why?
| | Thorax | 1 | 2013 | 52 | 0.130 |
Why?
| | Protons | 1 | 2013 | 94 | 0.130 |
Why?
| | Patient Care Team | 1 | 2016 | 275 | 0.130 |
Why?
| | Antibodies, Antinuclear | 3 | 2018 | 88 | 0.130 |
Why?
| | Young Adult | 6 | 2021 | 5970 | 0.130 |
Why?
| | Genetic Diseases, Inborn | 1 | 2014 | 99 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2018 | 1530 | 0.130 |
Why?
| | Comorbidity | 1 | 2017 | 937 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2019 | 685 | 0.130 |
Why?
| | Phantoms, Imaging | 2 | 2014 | 424 | 0.120 |
Why?
| | Mediastinitis | 1 | 2012 | 14 | 0.120 |
Why?
| | Cleft Palate | 1 | 2012 | 24 | 0.120 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2017 | 24 | 0.120 |
Why?
| | Histoplasmosis | 1 | 2012 | 23 | 0.120 |
Why?
| | Prostatic Neoplasms | 2 | 2020 | 1480 | 0.120 |
Why?
| | Dilatation, Pathologic | 1 | 2012 | 59 | 0.120 |
Why?
| | Time Factors | 5 | 2021 | 5496 | 0.120 |
Why?
| | Vital Capacity | 3 | 2017 | 62 | 0.120 |
Why?
| | Cardiac-Gated Imaging Techniques | 1 | 2012 | 22 | 0.120 |
Why?
| | Pericarditis, Constrictive | 1 | 2012 | 5 | 0.120 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2012 | 43 | 0.120 |
Why?
| | Cardiac Tamponade | 1 | 2012 | 19 | 0.120 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2011 | 23 | 0.120 |
Why?
| | Critical Care | 1 | 2015 | 362 | 0.120 |
Why?
| | Alleles | 1 | 2016 | 1116 | 0.120 |
Why?
| | Thoracic Diseases | 1 | 2012 | 26 | 0.120 |
Why?
| | Atlases as Topic | 1 | 2011 | 6 | 0.120 |
Why?
| | Chicago | 1 | 2017 | 1452 | 0.120 |
Why?
| | Inflammation | 1 | 2017 | 824 | 0.120 |
Why?
| | Heart Septum | 1 | 2012 | 51 | 0.120 |
Why?
| | T-Box Domain Proteins | 1 | 2012 | 100 | 0.110 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 821 | 0.110 |
Why?
| | Tomography, Spiral Computed | 1 | 2011 | 75 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1524 | 0.110 |
Why?
| | Bronchiectasis | 1 | 2010 | 12 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2012 | 291 | 0.110 |
Why?
| | Mitral Valve Insufficiency | 1 | 2012 | 175 | 0.100 |
Why?
| | Protein Kinases | 1 | 2011 | 224 | 0.100 |
Why?
| | Hypotension | 1 | 2010 | 74 | 0.100 |
Why?
| | Adolescent | 5 | 2021 | 9140 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2013 | 254 | 0.100 |
Why?
| | African Americans | 1 | 2018 | 1167 | 0.100 |
Why?
| | Fever | 1 | 2010 | 126 | 0.100 |
Why?
| | Italy | 2 | 2021 | 105 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2017 | 988 | 0.100 |
Why?
| | Delphi Technique | 3 | 2014 | 66 | 0.100 |
Why?
| | Adipose Tissue | 1 | 2012 | 260 | 0.100 |
Why?
| | Logistic Models | 3 | 2018 | 1158 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2018 | 898 | 0.100 |
Why?
| | Trachea | 1 | 2011 | 308 | 0.100 |
Why?
| | Bacteremia | 1 | 2010 | 117 | 0.100 |
Why?
| | Washington | 1 | 2009 | 42 | 0.100 |
Why?
| | Respiratory Function Tests | 2 | 2019 | 147 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2019 | 3877 | 0.090 |
Why?
| | Professional Competence | 1 | 2009 | 71 | 0.090 |
Why?
| | INDEL Mutation | 2 | 2018 | 26 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 387 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2019 | 1778 | 0.090 |
Why?
| | Palliative Care | 1 | 2010 | 254 | 0.090 |
Why?
| | Chest Pain | 2 | 2021 | 42 | 0.090 |
Why?
| | HIV Infections | 1 | 2016 | 714 | 0.090 |
Why?
| | Lung Injury | 2 | 2021 | 47 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 463 | 0.090 |
Why?
| | Smoking Cessation | 1 | 2010 | 178 | 0.090 |
Why?
| | Pyridines | 2 | 2020 | 308 | 0.080 |
Why?
| | Cholesterol, HDL | 2 | 2018 | 209 | 0.080 |
Why?
| | Receptors, Estrogen | 2 | 2020 | 382 | 0.080 |
Why?
| | Colonic Neoplasms | 1 | 2011 | 561 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 2426 | 0.080 |
Why?
| | DNA Mutational Analysis | 2 | 2018 | 538 | 0.080 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 813 | 0.080 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 114 | 0.070 |
Why?
| | Patient Selection | 2 | 2020 | 698 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 814 | 0.070 |
Why?
| | Ultrasonography | 2 | 2021 | 696 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 2 | 2020 | 566 | 0.070 |
Why?
| | Neoplasms | 1 | 2019 | 2692 | 0.070 |
Why?
| | Child | 3 | 2021 | 6768 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 870 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 1179 | 0.070 |
Why?
| | ROC Curve | 2 | 2019 | 761 | 0.060 |
Why?
| | Iopamidol | 2 | 2013 | 8 | 0.060 |
Why?
| | Child, Preschool | 2 | 2021 | 3758 | 0.060 |
Why?
| | Radiography | 2 | 2016 | 873 | 0.060 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 23 | 0.060 |
Why?
| | Signal Transduction | 3 | 2019 | 3301 | 0.060 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2020 | 23 | 0.050 |
Why?
| | New York | 1 | 2020 | 59 | 0.050 |
Why?
| | Gene Fusion | 1 | 2020 | 35 | 0.050 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 108 | 0.050 |
Why?
| | Cryosurgery | 1 | 2020 | 39 | 0.050 |
Why?
| | Psychotropic Drugs | 1 | 2021 | 77 | 0.050 |
Why?
| | Muscles | 1 | 2021 | 196 | 0.050 |
Why?
| | Chromosomes, Human, X | 1 | 2020 | 55 | 0.050 |
Why?
| | Ontario | 1 | 2020 | 55 | 0.050 |
Why?
| | Nicotinic Agonists | 1 | 2021 | 68 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2022 | 307 | 0.050 |
Why?
| | Cardiac Output | 1 | 2020 | 159 | 0.050 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2020 | 133 | 0.050 |
Why?
| | Body Composition | 1 | 2020 | 67 | 0.050 |
Why?
| | North America | 1 | 2020 | 180 | 0.050 |
Why?
| | Genetic Markers | 1 | 2021 | 493 | 0.050 |
Why?
| | Down-Regulation | 1 | 2021 | 524 | 0.050 |
Why?
| | Tumor Burden | 1 | 2021 | 287 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2227 | 0.050 |
Why?
| | Nicotine | 1 | 2021 | 169 | 0.050 |
Why?
| | Genomic Structural Variation | 1 | 2019 | 3 | 0.050 |
Why?
| | Telomerase | 1 | 2019 | 56 | 0.050 |
Why?
| | Organ Size | 1 | 2020 | 381 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 65 | 0.050 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 137 | 0.050 |
Why?
| | ras Guanine Nucleotide Exchange Factors | 1 | 2018 | 9 | 0.050 |
Why?
| | Nuclear Receptor Coactivators | 1 | 2018 | 4 | 0.050 |
Why?
| | Animals | 3 | 2018 | 26985 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 306 | 0.050 |
Why?
| | Neurofibromin 1 | 1 | 2018 | 7 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2020 | 176 | 0.050 |
Why?
| | Motion | 1 | 2019 | 75 | 0.050 |
Why?
| | Equipment Design | 1 | 2020 | 422 | 0.050 |
Why?
| | Consensus | 1 | 2020 | 293 | 0.050 |
Why?
| | Necrosis | 1 | 2019 | 208 | 0.050 |
Why?
| | NIH 3T3 Cells | 1 | 2018 | 107 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 51 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 41 | 0.050 |
Why?
| | Anilides | 1 | 2018 | 47 | 0.050 |
Why?
| | Mutation Rate | 1 | 2018 | 43 | 0.050 |
Why?
| | Hospitals | 1 | 2020 | 204 | 0.050 |
Why?
| | Odds Ratio | 1 | 2020 | 683 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 467 | 0.040 |
Why?
| | Gene Amplification | 1 | 2018 | 134 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2020 | 482 | 0.040 |
Why?
| | Propensity Score | 1 | 2018 | 131 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2017 | 87 | 0.040 |
Why?
| | Treatment Failure | 1 | 2018 | 303 | 0.040 |
Why?
| | Vasodilator Agents | 1 | 2019 | 180 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 143 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2022 | 677 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2019 | 286 | 0.040 |
Why?
| | Proteome | 1 | 2018 | 108 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 246 | 0.040 |
Why?
| | Phototherapy | 1 | 2017 | 35 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2018 | 233 | 0.040 |
Why?
| | Whole Body Imaging | 1 | 2017 | 37 | 0.040 |
Why?
| | Gene Dosage | 1 | 2018 | 216 | 0.040 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2017 | 109 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 177 | 0.040 |
Why?
| | Cause of Death | 1 | 2018 | 273 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2017 | 308 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2017 | 160 | 0.040 |
Why?
| | Pneumocystis carinii | 1 | 2016 | 3 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2015 | 1613 | 0.040 |
Why?
| | Length of Stay | 1 | 2020 | 697 | 0.040 |
Why?
| | Regression Analysis | 1 | 2018 | 625 | 0.040 |
Why?
| | Hypersplenism | 1 | 2016 | 2 | 0.040 |
Why?
| | Mice, Nude | 1 | 2018 | 785 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2017 | 194 | 0.040 |
Why?
| | Risk | 1 | 2018 | 700 | 0.040 |
Why?
| | Leukopenia | 1 | 2016 | 65 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 84 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 973 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2017 | 373 | 0.040 |
Why?
| | Silicosis | 1 | 2016 | 1 | 0.040 |
Why?
| | Asbestosis | 1 | 2016 | 5 | 0.040 |
Why?
| | Arthritis | 1 | 2016 | 45 | 0.040 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 102 | 0.040 |
Why?
| | Creatine Kinase | 1 | 2016 | 55 | 0.040 |
Why?
| | Neuroblastoma | 1 | 2020 | 363 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2018 | 369 | 0.040 |
Why?
| | Genetic Loci | 1 | 2017 | 238 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2017 | 482 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 1047 | 0.040 |
Why?
| | Sequence Alignment | 1 | 2016 | 366 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 343 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2020 | 627 | 0.040 |
Why?
| | Heart Rate | 1 | 2019 | 560 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2018 | 1196 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2016 | 414 | 0.040 |
Why?
| | Protein Multimerization | 1 | 2016 | 179 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2019 | 1102 | 0.040 |
Why?
| | Infant, Newborn | 1 | 2021 | 2438 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2017 | 331 | 0.040 |
Why?
| | Physical Examination | 1 | 2016 | 152 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 295 | 0.040 |
Why?
| | Lung Abscess | 1 | 2014 | 7 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 702 | 0.040 |
Why?
| | Hyperplasia | 1 | 2015 | 157 | 0.040 |
Why?
| | Multiple Trauma | 1 | 2014 | 31 | 0.040 |
Why?
| | Chromatin | 1 | 2017 | 344 | 0.040 |
Why?
| | Infant | 1 | 2021 | 3103 | 0.040 |
Why?
| | Body Mass Index | 1 | 2018 | 784 | 0.040 |
Why?
| | Pleural Effusion | 1 | 2014 | 47 | 0.040 |
Why?
| | Diaphragm | 1 | 2014 | 55 | 0.030 |
Why?
| | Mice | 2 | 2018 | 11133 | 0.030 |
Why?
| | Aortography | 1 | 2014 | 63 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2014 | 94 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 111 | 0.030 |
Why?
| | Foreign Bodies | 1 | 2014 | 64 | 0.030 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2013 | 13 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2100 | 0.030 |
Why?
| | Evidence-Based Dentistry | 1 | 2013 | 9 | 0.030 |
Why?
| | Bronchial Neoplasms | 1 | 2013 | 9 | 0.030 |
Why?
| | Tracheal Neoplasms | 1 | 2013 | 8 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 1434 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 890 | 0.030 |
Why?
| | Protein Conformation | 1 | 2016 | 893 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2017 | 694 | 0.030 |
Why?
| | Airway Obstruction | 1 | 2014 | 117 | 0.030 |
Why?
| | Cell Line | 1 | 2018 | 2615 | 0.030 |
Why?
| | Gene Order | 1 | 2012 | 25 | 0.030 |
Why?
| | Health Policy | 1 | 2014 | 170 | 0.030 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 446 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 275 | 0.030 |
Why?
| | Collagen Diseases | 1 | 2012 | 3 | 0.030 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2012 | 3 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1823 | 0.030 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2012 | 25 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 409 | 0.030 |
Why?
| | Liver | 1 | 2017 | 1246 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2016 | 2175 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2015 | 371 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2013 | 197 | 0.030 |
Why?
| | Embolization, Therapeutic | 1 | 2014 | 228 | 0.030 |
Why?
| | Rare Diseases | 1 | 2012 | 60 | 0.030 |
Why?
| | Diastole | 1 | 2012 | 149 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 672 | 0.030 |
Why?
| | Area Under Curve | 1 | 2011 | 345 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2012 | 209 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2020 | 2263 | 0.030 |
Why?
| | Computer Simulation | 1 | 2014 | 1059 | 0.020 |
Why?
| | Cell Survival | 1 | 2011 | 1012 | 0.020 |
Why?
| | Base Sequence | 1 | 2012 | 2430 | 0.020 |
Why?
| | Electrocardiography | 1 | 2010 | 583 | 0.020 |
Why?
|
|
Chung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|